Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Nektar Therapeutics (NASDAQ:NKTR) by 21.3% in the 1st quarter, HoldingsChannel reports. The fund owned 48,981 shares of the biopharmaceutical company’s stock after purchasing an additional 8,610 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Nektar Therapeutics were worth $1,646,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the business. FMR LLC grew its position in Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock valued at $853,355,000 after acquiring an additional 2,041,954 shares in the last quarter. Vanguard Group Inc grew its position in Nektar Therapeutics by 3.6% in the third quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock valued at $1,153,525,000 after acquiring an additional 660,907 shares in the last quarter. First Trust Advisors LP grew its position in shares of Nektar Therapeutics by 11.6% during the fourth quarter. First Trust Advisors LP now owns 2,309,172 shares of the biopharmaceutical company’s stock worth $75,902,000 after buying an additional 240,272 shares in the last quarter. Norges Bank acquired a new stake in shares of Nektar Therapeutics during the fourth quarter worth approximately $63,723,000. Finally, Bank of New York Mellon Corp grew its position in shares of Nektar Therapeutics by 1.3% during the fourth quarter. Bank of New York Mellon Corp now owns 1,418,699 shares of the biopharmaceutical company’s stock worth $46,634,000 after buying an additional 17,670 shares in the last quarter. 94.79% of the stock is owned by institutional investors.
In related news, CAO Jillian B. Thomsen sold 1,808 shares of the firm’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $42.39, for a total transaction of $76,641.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Howard W. Robin sold 42,215 shares of the firm’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $42.33, for a total value of $1,786,960.95. Following the transaction, the chief executive officer now owns 350,924 shares in the company, valued at $14,854,612.92. The disclosure for this sale can be found here. Insiders have sold 162,705 shares of company stock worth $6,872,756 over the last 90 days. 4.31% of the stock is currently owned by company insiders.
A number of analysts have recently weighed in on the stock. Mizuho reissued a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, January 23rd. ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. HC Wainwright reissued a “hold” rating and set a $47.00 price target on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 14th. Finally, BMO Capital Markets assumed coverage on shares of Nektar Therapeutics in a research report on Friday, February 22nd. They set an “outperform” rating and a $75.00 price target for the company. Two analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $69.73.
Shares of NKTR opened at $32.98 on Thursday. Nektar Therapeutics has a 12-month low of $29.22 and a 12-month high of $92.17. The firm has a market cap of $5.75 billion, a P/E ratio of 8.72 and a beta of 2.96. The company has a current ratio of 17.53, a quick ratio of 17.39 and a debt-to-equity ratio of 0.14.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 50.22% and a net margin of 57.09%. During the same quarter in the previous year, the firm earned ($0.60) EPS. As a group, analysts predict that Nektar Therapeutics will post -3.02 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 8,610 Shares of Nektar Therapeutics (NKTR)” was first posted by Equities Focus and is the property of of Equities Focus. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.equitiesfocus.com/2019/05/09/fjarde-ap-fonden-fourth-swedish-national-pension-fund-purchases-8610-shares-of-nektar-therapeutics-nktr.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.